No coherent doctrinal statement exists for calculating open-market damages for securities fraud class actions. Instead, courts have tried in vain to fashion common-law deceit and misrepresentation remedies to fit open-market fraud. The result is a relatively ineffective system with a hallmark feature: unpredictable damage awards. This poses a significant fraud deterrence problem from both a practical and a theoretical standpoint. In 2005, the Supreme Court had the opportunity to clarify open-market damage principles and to facilitate earlier dismissal of cases without compensable economic losses. Instead, in Dura Pharmaceuticals v. Broudo, it further confused the damage issue by (1) perpetuating the idea that courts can tailor dam...
With Amgen, the Supreme Court’s majority once again holds that inquiry into the alleged market impac...
On April 19, 2005, the United States Supreme Court rendered a unanimous decision in Dura Pharmaceuti...
Created pursuant to section 10 of the 1934 Securities Act, Rule 10b-5 is a cornerstone of the federa...
No coherent doctrinal statement exists for calculating open-market damages for securities fraud cl...
No coherent doctrinal statement exists for calculating open-market damages for securities fraud cl...
This short paper, originating in remarks made at the Institute for Law and Economic Policy\u27s 15...
Private suits have long been championed as a necessary mechanism not only to compensate investors fo...
The Supreme Court’s decision in Dura Pharmaceuticals dramatically changed federal securities fraud l...
In this article, I argue that securities fraud class actions (SFCAs) should not be treated as class ...
In this article, I argue that securities fraud class actions (SFCAs) should not be treated as class ...
In Halliburton Co. v. Erica P. John Fund, Inc. (Halliburton II), the United States Supreme Court rea...
In this article, I argue that securities fraud class actions (SFCAs) should not be treated as class ...
An issuer makes a positive, material misstatement in violation of Rule 10b-5. What must an investor ...
The class action device is vital to deterring securities fraud and remedying its victims, who almost...
As we have shown in a series of prior Articles, and as scholars have accepted since, class actions a...
With Amgen, the Supreme Court’s majority once again holds that inquiry into the alleged market impac...
On April 19, 2005, the United States Supreme Court rendered a unanimous decision in Dura Pharmaceuti...
Created pursuant to section 10 of the 1934 Securities Act, Rule 10b-5 is a cornerstone of the federa...
No coherent doctrinal statement exists for calculating open-market damages for securities fraud cl...
No coherent doctrinal statement exists for calculating open-market damages for securities fraud cl...
This short paper, originating in remarks made at the Institute for Law and Economic Policy\u27s 15...
Private suits have long been championed as a necessary mechanism not only to compensate investors fo...
The Supreme Court’s decision in Dura Pharmaceuticals dramatically changed federal securities fraud l...
In this article, I argue that securities fraud class actions (SFCAs) should not be treated as class ...
In this article, I argue that securities fraud class actions (SFCAs) should not be treated as class ...
In Halliburton Co. v. Erica P. John Fund, Inc. (Halliburton II), the United States Supreme Court rea...
In this article, I argue that securities fraud class actions (SFCAs) should not be treated as class ...
An issuer makes a positive, material misstatement in violation of Rule 10b-5. What must an investor ...
The class action device is vital to deterring securities fraud and remedying its victims, who almost...
As we have shown in a series of prior Articles, and as scholars have accepted since, class actions a...
With Amgen, the Supreme Court’s majority once again holds that inquiry into the alleged market impac...
On April 19, 2005, the United States Supreme Court rendered a unanimous decision in Dura Pharmaceuti...
Created pursuant to section 10 of the 1934 Securities Act, Rule 10b-5 is a cornerstone of the federa...